PrCP-7414 |
|
カタログ番号GC79578
|
PrCP-7414 is a prolyl carboxypeptidase ( PRCP ) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1252037-41-4
Sample solution is provided at 25 µL, 10mM.
In Vivo, PRCP-7414 (20 mg/kg, i.p., 5 days per week for 5 consecutive weeks) slows tumor growth in ER+ breast cancer PDX models in NSG mice, reduces the activation level of intratumoral AKT, and exerts a synergistic effect with Endoxifen to induce significant tumor regression[1]. PRCP-7414 (40 mg/kg; i.p.; 5 days per week; 51 days) inhibits the growth of triple-negative breast tumors in NOD SCID mice[2].
In Vitro, PRCP-7414 (5 μM; 72 h) inhibits the IGF1R/HER3-AKT signaling pathway in B6-9 breast cancer cells, enhances Endoxifen -induced cell death in both MCF7 and B6-9 breast cancer cells, and reduces their colony-forming ability[1]. PRCP-7414 (5 μM; 3 days) enhances the proliferation-inhibiting effect of Endoxifen on MCF7 and TRC breast cancer cells, as well as the cell death-inducing effect of Endoxifen on TRC breast cancer cells[1]. PrCP-7414 (1-10 μM; 3 days) reduces the viability of MCF7, BT549, MDA468, BT20, MDA231, Hs578T and SUM159PT breast cancer cells in a dose-dependent manner[2]. PrCP-7414 inhibits AKT activation downstream of EGFR, ErbB3, IGF1R and PDGFR in MDA468 and SUM159PT triple-negative breast cancer (TNBC) cells[2]. PrCP-7414 (5 μM-10 μM; 3 days) induces apoptosis in various triple-negative breast cancer (TNBC) cell lines[2]. PrCP-7414 (0-7.5 μM; 3 days) synergistically induces apoptosis of MDA468 and BT549 triple-negative breast cancer (TNBC) cells in combination with 2 μM Lapatinib [2].
References:
[1]. Duan L, et al. Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022;23(1):1-10.
[2]. Duan L, et al. Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers (Basel). 2022;14(3):739. Published 2022 Jan 31.
| Cas No. | 1252037-41-4 | SDF | |
| Formula | C31H33Cl2N5O2 | M.Wt | 578.53 |
| 溶解度 | DMSO: 100 mg/mL (172.85 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7285 mL | 8.6426 mL | 17.2852 mL |
| 5 mM | 345.7 μL | 1.7285 mL | 3.457 mL |
| 10 mM | 172.9 μL | 864.3 μL | 1.7285 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















